Phathom Pharmaceuticals annual operating income
2018
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Operating Income Growth & History (PHAT)
Phathom Pharmaceuticals's operating income was −$160.0M for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$160.0M | $117.5M | — |
| 2024 | 2024-12-31 | −$277.5M | −$110.2M | — |
| 2023 | 2023-12-31 | −$167.3M | $5.1M | — |
| 2022 | 2022-12-31 | −$172.4M | −$37.4M | — |
| 2021 | 2021-12-31 | −$135.1M | −$9.4M | — |
| 2020 | 2020-12-31 | −$125.7M | −$19.4M | — |
| 2019 | 2019-12-31 | −$106.2M | −$105.0M | — |
| 2018 | 2018-12-31 | −$1.2M | — | — |
Phathom Pharmaceuticals quarterly operating income
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.0M | $56.0M | — |
| Q1 2026 | 2026-03-31 | −$15.5M | $63.4M | — |
| Q4 2025 | 2025-12-31 | −$5.9M | $53.5M | — |
| Q3 2025 | 2025-09-30 | −$15.3M | $55.5M | — |
| Q2 2025 | 2025-06-30 | −$59.9M | $17.4M | — |
| Q1 2025 | 2025-03-31 | −$78.9M | −$8.9M | — |
| Q4 2024 | 2024-12-31 | −$59.4M | $10.5M | — |
| Q3 2024 | 2024-09-30 | −$70.8M | −$35.1M | — |
| Q2 2024 | 2024-06-30 | −$77.3M | −$45.6M | — |
| Q1 2024 | 2024-03-31 | −$70.0M | −$39.9M | — |
| Q4 2023 | 2023-12-31 | −$69.9M | −$23.2M | — |
| Q3 2023 | 2023-09-30 | −$35.7M | $6.9M | — |
| Q2 2023 | 2023-06-30 | −$31.7M | $13.7M | — |
| Q1 2023 | 2023-03-31 | −$30.1M | $7.8M | — |
| Q4 2022 | 2022-12-31 | −$46.6M | −$13.6M | — |
| Q3 2022 | 2022-09-30 | −$42.5M | −$9.4M | — |
| Q2 2022 | 2022-06-30 | −$45.4M | −$10.0M | — |
| Q1 2022 | 2022-03-31 | −$37.9M | −$4.3M | — |
| Q4 2021 | 2021-12-31 | −$33.0M | $19.4M | — |
| Q3 2021 | 2021-09-30 | −$33.1M | −$307,000 | — |
| Q2 2021 | 2021-06-30 | −$35.3M | −$15.3M | — |
| Q1 2021 | 2021-03-31 | −$33.6M | −$13.2M | — |
| Q4 2020 | 2020-12-31 | −$52.4M | −$36.7M | — |
| Q3 2020 | 2020-09-30 | −$32.8M | −$26.5M | — |
| Q2 2020 | 2020-06-30 | −$20.0M | $63.0M | — |
| Q1 2020 | 2020-03-31 | −$20.4M | −$19.1M | — |
| Q4 2019 | 2019-12-31 | −$15.7M | −$15.2M | — |
| Q3 2019 | 2019-09-30 | −$6.3M | −$6.0M | — |
| Q2 2019 | 2019-06-30 | −$83.0M | −$82.8M | — |
| Q1 2019 | 2019-03-31 | −$1.2M | −$975,000 | — |
| Q4 2018 | 2018-12-31 | −$451,000 | — | — |
| Q3 2018 | 2018-09-30 | −$268,000 | — | — |
| Q2 2018 | 2018-06-30 | −$255,000 | — | — |
| Q1 2018 | 2018-03-31 | −$251,000 | — | — |
Phathom Pharmaceuticals operating income trends
Over the last five fiscal years, Phathom Pharmaceuticals's operating income decreased from −$125.7M to −$160.0M, a change of −$34.3M. The latest reported quarter, Q2 2026, shows −$4.0M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
